IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma

Lakshmi Nayak, Christian Grommes, Charles Psoinos, Frederic J Reu, Akira Takazawa, Mayur Uttarwar, Binfeng Xia, Luis A Carvajal, Soojin Kim, Matthew L Sherman, Tracy T Batchelor · 2026

Read IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma by Lakshmi Nayak, Christian Grommes, Charles Psoinos, Frederic J Reu, Akira Takazawa, Mayur Uttarwar, Binfeng Xia, Luis A Carvajal, Soojin Kim, Matthew L Sherman, Tracy T Batchelor (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13374761.txt.

Description

Lakshmi Nayak and co-authors lay out a large drug trial for a rare brain cancer in a 2026 paper. The cancer is a fast lymph growth that starts in the brain or spine. First care works at first for most, but the cancer tends to come back, and passed cures for that stage are few.

The new drug blocks a growth switch and is passed for this use in three Asian lands. The world trial pits it, one to one, against a two-drug mix in an open plan. The main score is time with no growth, read by blind staff. A win could give the West its first passed cure for this hard stage.

Catalog record

CREATORLakshmi Nayak, Christian Grommes, Charles Psoinos, Frederic J Reu, Akira Takazawa, Mayur Uttarwar, Binfeng Xia, Luis A Carvajal, Soojin Kim, Matthew L Sherman, Tracy T Batchelor
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE30846
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13374761

Browse the full library · About the Tower of Babel